Latest Regulatory News

First Graphene Limited reveals significant progress in commercialising its PureGRAPH graphene technology, highlighting expanding global partnerships and a robust sales pipeline valued over A$10 million.

My Foodie Box Limited is set to pivot from meal kits to mining by acquiring Australian gold, copper, and rare earth projects, renaming itself Tarrina Resources, and relisting on the ASX with a $5 million capital raise.

Coast Entertainment Holdings faces a potential regulatory intervention as Queensland's Deputy Premier signals intent to take over assessment of its Dreamworld land development application, citing state economic and environmental interests.

Halo Technologies Holdings Ltd has announced a renounceable pro rata rights issue aiming to raise up to $11 million at $0.024 per share, partially underwritten by Lodge Corporate Pty Ltd. The capital raise will support the company’s UK market entry, local growth, and ongoing software development.

PT Aneka Tambang Tbk (ANTAM) posted a 7% increase in sales to Rp23.19 trillion in the first half of 2024, driven by strong domestic gold sales, and reported a net profit of Rp1.51 trillion. The company also completed significant divestments, retaining control of SDA while divesting majority ownership in FHT.

Pro Medicus’s U.S. subsidiary Visage Imaging has earned a critical Authority to Operate from the U.S. Department of Veterans’ Affairs, enabling its Visage 7 CloudPACS platform to transition to the Veterans Affairs Enterprise Cloud.

Orezone Gold Corporation has clarified that it has not received any government request for equity participation in its Bomboré Gold Mine and will resume trading on the ASX. The company also provided updates on its mine expansion and production outlook.

Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.

The ASX has suspended trading in six companies starting 1 September 2025 due to late lodgement of mandatory periodic reports. The suspension may be lifted quickly if reports are filed promptly.

Lumos Diagnostics, backed by BARDA, is set to begin a pivotal pediatric clinical study to extend the use of its rapid respiratory infection test, FebriDx, to children aged 2–12 in U.S. CLIA-waived settings, potentially unlocking a $1 billion market.

Canyon Resources’ Definitive Feasibility Study confirms Minim Martap as a major bauxite project with a 33% ore reserve increase and robust economics, targeting production start in early 2026.

Imricor Medical Systems has taken a significant step toward U.S. market entry by submitting its Vision-MR Diagnostic Catheter for FDA 510(k) approval, complementing its recent NorthStar system filing. These moves aim to establish a fully integrated MRI-guided cardiac ablation platform.